financial for wish as prepare our also and to leadership additions as registration-directed he John we personnel, three Henson finance, his which included included core commanding where behalf welcome want team, all since to Marc Pete, and after his officer. had spent of the earned position years and in on members operations John lead her at the all them leadership, take in the chief an Air in dedication space, joining banker team August operations, Celgene all thank years officer Receptos Doctorate transactions, the in Marc biology corporate leadership our development. chief chief operations healthcare of raising entire you assurance, operating investment in John Coast history and inception. focused management leadership appreciation valuable last Stifel pharmaceutical of Johns the and as significant a like into recently hard Marine On Marc CFO the from banking to seamlessly and working the and Officer. will best. is for for team functions joined to sincere we opportunity and clinical by as Kura's the with the board where her I start help ensure Medicine Previously, of to officer deep and an strength Station and strategic together. strategic us University first Heidi career you, oversaw responsibilities Thank Hopkins I'd Marc on degree Kura. to undergraduate capital he our He Marc person services Farnam biopharma. and finance, distinguished for advisory want most head us he express of Kura's in this and and of the Medicine work newly I thank officer personnel. newest business at this created for leading X,XXX of companies, of installation Kura trial molecular Princeton XX. and Miramar where us of With a program Grasso He'll role to quality professional facilities John's us both as Dr. comes West of step to from knowledge in my biotechnology are start to this company's operations, ideal as exposure expanded services month our and Farnam. afternoon. University. leadership introducing its past XX Corps, School are to at that
drug lead of me our brief multiple with a candidate, tipifarnib. tipifarnib solid Now, tumor evaluating you each hematologic on update and programs currently indications. give We're let our development in beginning
HNSCC. carcinomas, HNSCC of advanced cell had Our primary we HRAS efficacy neck endpoint RUN-HN. achieved to Last its and our trial We mutant is indication prior head ongoing squamous mutant, in most announced enrollment. call fall, completion tipifarnib HRAS II this that of or in Phase trial
As of confirmed with of intent-to-treat update we patients data our of five six in responses response reported median six months. nine on than or five an duration more February, evaluable patients of last basis, in of a
in XX% Munich at reminder, the next the XX%. a the squamous for in HRAS second cell to XXXX in in other European Society plan three the from October. of response Medical As our are of We exploratory update this an approved to line Congress rates in present cohort, Oncology including mutant carcinomas patients for agents range presentation trial, oral
call, provides As oncology-focused to our make continue next-generation support HNSCC including our patients the agreement a oncogenic with for physicians in technology We've to identify treatment internationally last based HRAS Belgium, sequencing may on with significant HRAS whom signed we OncoDNA discussed option. screen to tipifarnib healthcare and an mutations patients population. OncoDNA, ability an we company for patient enrollment. overall strides mutations, with be in with potential among
enrollment with OncoDNA, progressing also on With we recently patients first who setting in our our patient HNSCC manner, identifying identifying mutant of we treatment with in HRAS later frontline this HRAS and tracking patient patients the newly-diagnosed the RUN-HN those in for enrolled enrolled study. a frontline treatment. are mutant help HNSCC in potential Indeed, after
additional sites study We now approximately for with open worldwide, open XX enrollment. locations clinical to continue
we designed which factors should years primary initiated trial last pattern we the This histology or squamous to of with of global, upon history order those Spanish study, date this To metastatic trial type, patients and designed mutant with lung clinical HRAS potential non-interventional has cohort, our later line as as cohort. to investigator-sponsored registration-directed multicenter to age, a assumptions, for type patients for trial. using a considered that LSCC, results similar of a these interest. treatment at and with XXX mutations, provide trial SEQ-HN to well of cell rate. genetic with SEQ-HN trial study Cancer AIM-HN. We're as Group, This these responses is initiate support therapy, is cohorts is AIM-HN wild enrollment as to two the recognize a and such is XX a preparing of point approximately mutant we're the patients take need potential as HNSCC of rate activities to a and Spain Meanwhile, the HRAS platinum-based tipifarnib efficacy second-line treatment. approximately designed patients natural case-control mutations in HNSCC. cooperative two in XXX us call, as evaluate of a difference initiated confirmed endpoint and LSCC than with response reject of concept study collaborating therapy, Lung for received enrollment. should fully with and XX of This hypothesis HRAS in been this observed year. commitments the ORR, the least of enrolling private identify therapy. from group a opportunity SEQ-HN, treat considerations. of better the registration-directed AIM-HN, while patients a potential Based null are well now helping and result HRAS between proof power mutant and more for and NDA tipifarnib us and this overall in the with public endpoint. – who who commercial close the a mutant a carcinoma the to recurrent XX% are XX%, could as into has HRAS estimate tipifarnib enroll. in understanding post-approval matching consists outcomes trial on to screening of prior few is The The HNSCC. meet As to approximately with HRAS at its Based month also against or recurrent feedback the as in for primary targeting also have per FDA, expect AIM-HN centers is as metastatic startup disease encouraging we're now Since HRAS sites open of HNSCC now we've RUN-HN patients detect and on opportunity, ORR oncology two the RUN-HN. has XX% worldwide in efforts, of hypothesis positive statistical null in
and We clinical continue the the very generated tipifarnib as preclinical encouraged we've mutations. tumors data of to for treatment characterized by solid by potential supporting be a HRAS
in Our data use to is HRAS mutant an for to a to other we possible, soon unmet its potential need. approval work marketing as while high HNSCC of diseases to as support goal include broaden application package generate
tipifarnib that our patients malignancies in Now, our can a for in attention MDS tipifarnib. activity Previously hematologic represent clinical AML, opportunity turn studies also with malignancies, and conducted demonstrated let's which development strategy PTCL. drive hematologic including certain to significant
hematologic is AITL first as ongoing begin was in or been of CXCL-XX of patients prospectively with no Based of its molecular XXXX, CXCL-XX a we on potential two activation who MDS region actively cells in and in cohorts. to prime and single PTCL those Phase AML. in including activity target certain the of three and the T-cell CMML However, myeloid that to malignancies, potential biomarkers of we've of presented with therapeutic neoplasias, trials. marrow a the the action lymphoma identified into the untranslated findings mechanism PTCL of populations. to as and activity and variation The pathway our explain observations, identified absence pathway biomarkers enrolling II X' the of could Patients angioimmunoblastic CXCL-XX PTCL, was and patient myeloid continue bone have validate In tipifarnib nucleotide gene. that validate homing new December tipifarnib's working trial these to three
CXCL-XX other forward the from hematologic of will end to indications continue PTCL to this and year. providing pathway encouraged biomarker-enriched we tipifarnib to for be potentially promise who and respond the look by We patients holds initial that identifying data
ERK quickly kinase have tumors or activity pathway. attention pipeline our mutations with let's as to two turn with emerging patients beginning the for inhibitor, treatment due our a programs, We're KO-XXX. in mechanisms advancing to that potential dysregulated other KO-XXX Now, MAP
is escalation schedule tumors KO-XXX ERK dose patients, dose will in in solid that to tumors I KO-XXX evaluate genetically-selected define inhibition. to sensitive We're whose ongoing. working are Phase enable and a trial Our to of us
with potential expect and demonstrated clinical advancing clinical leukemia, expecting small of for selective genetically-defined Given has oncogenic completion molecule successful acute we in late activity data present that in early those in escalation of NPMX- that submit application currently we're the studies, a trial, next I IND-enabling menin-MLL We're dose now to to and year. subsets KO-XXX, mutations the IND potent still we're inhibitor an of XXXX. also or driver KO-XXX in Pending XXXX interaction Phase including antitumor phase the of DNMTXA.
loss administrative of the quarter second quarter increase compensation, to XXXX. $X.X call second increase XXXX per expenses the $X.X expenses quarter due $X.X per to more R&D on expenses Next, loss invite review the The $XX.X tipifarnib. or Research provide of the quarter here G&A million the of today were quarter for patent-related million and to XXXX. XXXX compared I'll share-based development quick financial overview the and clinical for for compared activities to net of primarily XXXX and our in filed or fees detailed quarter increases second a $X.XX quarter and of million share XX-Q in costs. increase in second second a $XX.X you $X.XX the were XXXX. a was due related for to non-cash second to discussion. The for million was million expenses an was primarily to results $XX.X professional Net our of of for for million General compared the in development share for
XXXX, of short-term XXXX. XXXX had million July cash As with public stock. June on XX, equivalents we compared a of cash, of as Subsequently, December common offering X, $XXX.X completed and of million we $XX.X investments XX,
XX, adjusted As equivalents a net had at in $XX.X from in Kura cash the public and proceeds the June XXXX. pro million for on investments cash, million forma offering, resulting $XXX.X basis
July our We terminated ATM facility in also XX.
who the I'd participated resources mutant our leadership balance be our second will offering HNSCC. in in HRAS million, progress vote confidence. approximately cash, we've and including operations We everyone our the half thank to pipeline of the We I'm registration upcoming with a our equivalents investments our of of strengthened year your opportunities on to the past $XXX potential positioned data our made with execution. to team, We've through like current us that current our very advance the milestones, operational our from identify a focus HRAS series mutations, directed sheet. ability pleased with additional create improved giving of patients and to for screen began fund trial over expect to quarter sufficient with upcoming tipifarnib and pipeline enhanced cash through short-term XXXX. recent
for look forward updates will we value in and you, grateful are significant toward our support ahead. your attention work for your appreciate patients afternoon and I for We shareholders. and to continue months to the providing additional this creating
Before we milestones. into the quickly Q&A me jump layout let anticipated our section,
initiation our end of this of by year. For tipifarnib, the registration-directed trial
Additional ongoing from our trial mutant carcinomas exploratory other data cohort our RUN-HN in at an cell and HRAS presentation squamous oral of ESMO.
cell the dosed biomarker-enriched the potentially this end of data malignancies carcinoma and in patient other and squamous investigator-sponsored in First study mutant by HRAS lung year. hematologic PTCL
we're late operator, XXXX trial now for KO-XXX, for in early XXXX; submission dose questions. an and With in IND ready XXXX. of For data I that, application or our KO-XXX, from escalation Phase
